These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 31733412)

  • 21. Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization.
    Gaibani P; Re MC; Campoli C; Viale PL; Ambretti S
    Clin Microbiol Infect; 2020 Apr; 26(4):516.e1-516.e4. PubMed ID: 31740422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful ceftazidime-avibactam treatment of MDR-KPC-positive Klebsiella pneumoniae infection in a patient with traumatic brain injury: A case report.
    Gugliandolo A; Caio C; Mezzatesta ML; Rifici C; Bramanti P; Stefani S; Mazzon E
    Medicine (Baltimore); 2017 Aug; 96(31):e7664. PubMed ID: 28767588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emergence of ceftazidime-avibactam resistance due to a novel blaKPC-2 mutation during treatment of carbapenem-resistant Klebsiella pneumoniae infections.
    Liao Q; Deng J; Feng Y; Zhang W; Wu S; Liu Y; Che H; Xie Y
    J Infect Public Health; 2022 May; 15(5):545-549. PubMed ID: 35461077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne
    Shields RK; Chen L; Cheng S; Chavda KD; Press EG; Snyder A; Pandey R; Doi Y; Kreiswirth BN; Nguyen MH; Clancy CJ
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031201
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.
    Santevecchi BA; Smith TT; MacVane SH
    Int J Antimicrob Agents; 2018 Apr; 51(4):629-635. PubMed ID: 29408227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cure of recurring Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae septic shock episodes due to complicated soft tissue infection using a ceftazidime and avibactam-based regimen: a case report.
    Parruti G; Frattari A; Polilli E; Savini V; Sciacca A; Consorte A; Cibelli DC; Agostinone A; Di Masi F; Pieri A; Cacciatore P; Di Iorio G; Fazii P; Spina T
    J Med Case Rep; 2019 Jan; 13(1):20. PubMed ID: 30665450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of KPC Variant and Porin Genotype on the
    Wilson WR; Kline EG; Jones CE; Morder KT; Mettus RT; Doi Y; Nguyen MH; Clancy CJ; Shields RK
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617090
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms.
    Temkin E; Torre-Cisneros J; Beovic B; Benito N; Giannella M; Gilarranz R; Jeremiah C; Loeches B; Machuca I; Jiménez-Martín MJ; Martínez JA; Mora-Rillo M; Navas E; Osthoff M; Pozo JC; Ramos Ramos JC; Rodriguez M; Sánchez-García M; Viale P; Wolff M; Carmeli Y
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895014
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Adams J; Santarossa M; Harrington A; Bauer M; Wozniak A; Labuszewski L; Albarillo FS
    Infect Dis (Lond); 2023 Apr; 55(4):282-291. PubMed ID: 36772806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emergence and Recovery of Ceftazidime-avibactam Resistance in blaKPC-33-Harboring Klebsiella pneumoniae Sequence Type 11 Isolates in China.
    Shi Q; Yin D; Han R; Guo Y; Zheng Y; Wu S; Yang Y; Li S; Zhang R; Hu F
    Clin Infect Dis; 2020 Dec; 71(Suppl 4):S436-S439. PubMed ID: 33367577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates.
    Gaibani P; Lewis RE; Volpe SL; Giannella M; Campoli C; Landini MP; Viale P; Re MC; Ambretti S
    Int J Infect Dis; 2017 Dec; 65():1-3. PubMed ID: 28951106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activity of Ceftazidime-Avibactam Alone and in Combination with Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing
    Ojdana D; Gutowska A; Sacha P; Majewski P; Wieczorek P; Tryniszewska E
    Microb Drug Resist; 2019 Nov; 25(9):1357-1364. PubMed ID: 31295055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-Resistant
    Athans V; Neuner EA; Hassouna H; Richter SS; Keller G; Castanheira M; Brizendine KD; Mathers AJ
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30578403
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Shields RK; Nguyen MH; Press EG; Chen L; Kreiswirth BN; Clancy CJ
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
    Sader HS; Castanheira M; Flamm RK
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant
    Ackley R; Roshdy D; Meredith J; Minor S; Anderson WE; Capraro GA; Polk C
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ceftazidime/avibactam and eravacycline susceptibility of carbapenem-resistant Klebsiella pneumoniae in two Greek tertiary teaching hospitals.
    Chatzidimitriou M; Chatzivasileiou P; Sakellariou G; Kyriazidi M; Kavvada A; Chatzidimitriou D; Chatzopoulou F; Meletis G; Mavridou M; Rousis D; Katsifa E; Vagdatli E; Mitka S; Theodoros L
    Acta Microbiol Immunol Hung; 2021 Jun; 68(2):65-72. PubMed ID: 33522985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia.
    Shields RK; Nguyen MH; Chen L; Press EG; Potoski BA; Marini RV; Doi Y; Kreiswirth BN; Clancy CJ
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559250
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro antibacterial activity of ceftazidime/avibactam in combination against planktonic and biofilm carbapenemase-producing Klebsiella pneumoniae isolated from blood.
    Papalini C; Sabbatini S; Monari C; Mencacci A; Francisci D; Perito S; Pasticci MB
    J Glob Antimicrob Resist; 2020 Dec; 23():4-8. PubMed ID: 32810638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Several key points that need to be concerned in the clinical application of ceftazidime/avibactam].
    Tang B; Cui N
    Zhonghua Yi Xue Za Zhi; 2021 Nov; 101(41):3365-3370. PubMed ID: 34758539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.